guest ::
| Home > Publications Database > Crispr/Cas-based modeling of NF2 loss in meningioma cells. > print |
| 001 | 157728 | ||
| 005 | 20240123093027.0 | ||
| 024 | 7 | _ | |a 10.1016/j.jneumeth.2021.109141 |2 doi |
| 024 | 7 | _ | |a pmid:33753124 |2 pmid |
| 024 | 7 | _ | |a 0165-0270 |2 ISSN |
| 024 | 7 | _ | |a 1872-678X |2 ISSN |
| 024 | 7 | _ | |a altmetric:102532506 |2 altmetric |
| 037 | _ | _ | |a DZNE-2021-01185 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Waldt, Natalie |b 0 |
| 245 | _ | _ | |a Crispr/Cas-based modeling of NF2 loss in meningioma cells. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2021 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1705998584_18611 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Alterations of the neurofibromatosis type 2 gene (NF2) occur in more than fifty percent of sporadic meningiomas. Meningiomas develop frequently in the setting of the hereditary tumor syndrome NF2. Investigation of potential drug-based treatment options has been limited by the lack of appropriate in vitro and in vivo models.Using Crispr/Cas gene editing, of the malignant meningioma cell line IOMM-Lee, we generated a pair of cell clones characterized by either stable knockout of NF2 and loss of the protein product merlin or retained merlin protein (transfected control without gRNA).IOMM-Lee cells lacking NF2 showed reduced apoptosis and formed bigger colonies compared to control IOMM-Lee cells. Treatment of non-transfected IOMM-Lee cells with the focal adhesion kinase (FAK) inhibitor GSK2256098 resulted in reduced colony sizes. Orthotopic mouse xenografts showed the formation of convexity tumors typical for meningiomas with NF2-depleted and control cells.No orthotopic meningioma models with genetically-engineered cell pairs are available so far.Our model based on Crispr/Cas-based gene editing provides paired meningioma cells suitable to study functional consequences and therapeutic accessibility of NF2/merlin loss. |
| 536 | _ | _ | |a 351 - Brain Function (POF4-351) |0 G:(DE-HGF)POF4-351 |c POF4-351 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Crispr/Cas |2 Other |
| 650 | _ | 7 | |a Meningioma |2 Other |
| 650 | _ | 7 | |a Neurofibromatosis type 2 (NF2) |2 Other |
| 650 | _ | 7 | |a Neurofibromin 2 |2 NLM Chemicals |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Cell Line, Tumor |2 MeSH |
| 650 | _ | 2 | |a Clustered Regularly Interspaced Short Palindromic Repeats: genetics |2 MeSH |
| 650 | _ | 2 | |a Meningeal Neoplasms: genetics |2 MeSH |
| 650 | _ | 2 | |a Meningioma: genetics |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Neurofibromin 2: genetics |2 MeSH |
| 650 | _ | 2 | |a Neurofibromin 2: metabolism |2 MeSH |
| 700 | 1 | _ | |a Kesseler, Christoph |b 1 |
| 700 | 1 | _ | |a Fala, Paula |b 2 |
| 700 | 1 | _ | |a John, Peter |b 3 |
| 700 | 1 | _ | |a Kirches, Elmar |b 4 |
| 700 | 1 | _ | |a Angenstein, Frank |0 P:(DE-2719)2810456 |b 5 |u dzne |
| 700 | 1 | _ | |a Mawrin, Christian |b 6 |
| 773 | _ | _ | |a 10.1016/j.jneumeth.2021.109141 |g Vol. 356, p. 109141 - |0 PERI:(DE-600)1500499-5 |p 109141 |t Journal of neuroscience methods |v 356 |y 2021 |x 0165-0270 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/157728/files/DZNE-2021-01185_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/157728/files/DZNE-2021-01185_Restricted.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:157728 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2810456 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-351 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Brain Function |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-27 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-12 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-12 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEUROSCI METH : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-12 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-12 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-2719)1310004 |k AG Angenstein |l Functional Neuroimaging |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1310004 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|